Form 4: IQVIA Executive Bhavik Patel Reports Stock Transactions

IQVIA Holdings Inc. President, MedTech and Consumer Health, Bhavik Patel, reported the acquisition of shares from performance-based restricted stock units and subsequent tax-related dispositions.

Summary

• Bhavik Patel, President, MedTech and Consumer Health, acquired 4,083 shares of IQVIA Holdings Inc. common stock on February 8, 2026.
• These shares were acquired upon the achievement of performance criteria related to restricted stock units granted on February 13, 2023, with the Company's Leadership Development and Compensation Committee confirming satisfaction of conditions on February 8, 2026.
• Following this acquisition, Patel's beneficial ownership increased to 5,123 shares.
• Concurrently, Patel disposed of 1,920 shares of common stock on February 8, 2026, at a price of $187.49 per share, primarily for tax withholding purposes.
• After both transactions, Patel's direct beneficial ownership stands at 3,203 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the successful vesting of performance-based compensation for an executive, which indicates achieved company goals, offset by a routine tax-related disposition.

Positives

• The acquisition of 4,083 shares by Bhavik Patel indicates the successful achievement of performance criteria for restricted stock units granted in February 2023.
• This vesting demonstrates the company's leadership meeting specific, pre-defined performance goals, aligning executive incentives with shareholder value.

Negatives

• The disposition of 1,920 shares, while likely for tax purposes, reduces the executive's direct beneficial ownership in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Performance conditions applicable to the award were determined to have been satisfied by the Company's Leadership Development and Compensation Committee on February 8, 2026.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions, reflecting executive compensation structures common across industries, particularly the vesting of performance-based equity awards. This type of transaction is a standard component of executive incentive plans designed to align management interests with long-term company performance.

Comparison to Industry Standards

• The vesting of performance-based restricted stock units is a common executive compensation practice across the pharmaceutical services and healthcare technology industries, similar to structures seen at companies like Laboratory Corporation of America Holdings (LH) or Charles River Laboratories International, Inc. (CRL).
• The subsequent disposition of shares for tax withholding is also a standard procedure upon the vesting of equity awards, consistent with practices observed in executive compensation programs globally.

Stakeholder Impact

• Shareholders: The vesting of performance-based equity aligns executive incentives with company performance, potentially benefiting long-term shareholder value.
• Employees: This transaction demonstrates the company's established executive compensation framework, which can influence broader employee incentive programs.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance-based restricted stock units and a subsequent tax-related disposition. It does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. It simply confirms an expected compensation event for an insider.

Keywords

IQVIA, IQV, Form 4, insider trading, stock transaction, executive compensation, restricted stock units, Bhavik Patel